2021
DOI: 10.1016/j.annonc.2021.05.208
|View full text |Cite
|
Sign up to set email alerts
|

P-153 Safety and effectiveness of sorafenib in elderly patients diagnosed with advanced hepatocellular carcinoma in a monographic oncologic center

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…Sepulveda et al aimed to determine the impact of age, comorbidities, and initial dose reduction on the efficacy and safety of sorafenib among 202 older patients included in a retrospective analysis [3], where 23% (n = 45) of patients were ≥ 75 years. Over 90% of patients had an ECOG PS 0-1; no GA was performed.…”
Section: P-153 Safety and Effectiveness Of Sorafenib In Elderly Patients Diagnosed With Advanced Hepatocellular Carcinoma In A Monographimentioning
confidence: 99%
“…Sepulveda et al aimed to determine the impact of age, comorbidities, and initial dose reduction on the efficacy and safety of sorafenib among 202 older patients included in a retrospective analysis [3], where 23% (n = 45) of patients were ≥ 75 years. Over 90% of patients had an ECOG PS 0-1; no GA was performed.…”
Section: P-153 Safety and Effectiveness Of Sorafenib In Elderly Patients Diagnosed With Advanced Hepatocellular Carcinoma In A Monographimentioning
confidence: 99%